(Q37025942)

17 August 2017

1 reference

title

Molecular markers for bladder cancer: the road to a multimarker approach (English)

1 reference

17 August 2017

1 reference

Marc Birkhahn

1

1 reference

PubMed ID

18062746

17 August 2017

Anirban P Mitra

series ordinal

2

1 reference

PubMed ID

18062746

17 August 2017

Richard J Cote

series ordinal

3

1 reference

17 August 2017

1 December 2007

1 reference

Expert Review of Anticancer Therapy

17 August 2017

1 reference

17 August 2017

7

1 reference

17 August 2017

1717-1727

1 reference

17 August 2017

12

1 reference

17 August 2017

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

The health economics of bladder cancer: a comprehensive review of the published literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

The diagnosis and staging of bladder cancer: from RBCs to TURs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Cancer. p53, guardian of the genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

p53 mutations in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Accumulation of nuclear p53 and tumor progression in bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

P53 as a prognostic marker for bladder cancer: a meta-analysis and review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

p150(Sal2) is a p53-independent regulator of p21(WAF1/CIP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

p14ARF links the tumour suppressors RB and p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

The E2F transcription factor is a cellular target for the RB protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Altered Expression of Retinoblastoma Protein and Known Prognostic Variables in Locally Advanced Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Decreasing of p27(Kip1)and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

The predictive value of p53, p27(kip1), and alpha-catenin for progression in superficial bladder carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Expression of G1-->S transition regulatory molecules in human urothelial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Drug-target interactions: only the first step in the commitment to a programmed cell death?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Apoptosis and its clinical significance for bladder cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

21 January 2018

Regulators of cell death

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Involvement of mitochondrial pathway in Taxol-induced apoptosis of human T24 bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Validating survivin as a cancer therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Survivin study: what is the next wave?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Survivin: a promising tumor biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Prognostic value of cell cycle regulatory proteins in muscle-infiltrating bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Mass spectrometry-based proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Proteomics: a technology-driven and technology-limited discovery science

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

p53 and treatment of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12.1717

10.1586/14737140.7.12.1717

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

18062746